# Why AstraZeneca Bought Equity in Syneron Bio — Not Just a License - Date: 2026-04-06 - Category: Biotech & Life Sciences AstraZeneca didn’t just license Syneron Bio’s peptide platform — it co-invested. That equity stake, layered on top of $75M upfront and $3.4B in milestones, signals a different kind of pharma bet: conviction in the factory, not just the product. ---